2 weeks Ago By Defense World Staff
Cerity Partners LLC lowered its position in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 35.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission.
The institutional investor owned 1,532 shares of the medical instruments supplier’s stock after selling 858 shares during the quarter. Cerity Partners LLC’s holdings in Glaukos were worth $230,000 at the end of the most recent quarter. Other hedge funds and other institutional investors also recently bought and sold shares of the company.
IFP Advisors Inc bought a new stake in Glaukos during the fourth quarter worth approximately $43,000. Asset Planning Inc acquired a new position in shares of Glaukos during the 4th quarter valued at about $90,000. Picton Mahoney Asset Management acquired a new stake in shares of Glaukos in the fourth quarter valued at about $125,000.
SBI Securities Co. Ltd. bought a new position in shares of Glaukos in the fourth quarter worth about $153,000.
Finally, Smartleaf Asset Management LLC lifted its position in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 807 shares during the last quarter.
99.04% of the stock is currently owned by institutional investors and hedge funds. Insider ActivityIn other news, CFO Alex R.
Thurman sold 1,520 shares of the business’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.
80. Following the sale, the chief financial officer now owns 53,431 shares of the company’s stock, valued at $5,708,568.04.
The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Also, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.
24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18.
This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here.
Corporate insiders own 6.40% of the company’s stock. Glaukos Stock Up 2.
8 %Shares of Glaukos stock opened at $95.20 on Friday. The company has a market capitalization of $5.
39 billion, a P/E ratio of -33.17 and a beta of 0.88.
The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.
71. The business has a 50-day moving average of $103.49 and a two-hundred day moving average of $130.
35. Glaukos Co. has a 1 year low of $77.
91 and a 1 year high of $163.71. Glaukos (NYSE:GKOS – Get Free Report) last announced its earnings results on Thursday, February 20th.
The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.
02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.
04%. The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.
72 million. As a group, equities analysts predict that Glaukos Co. will post -1.
08 EPS for the current year. Wall Street Analyst Weigh InSeveral research analysts have commented on GKOS shares. Truist Financial dropped their price target on Glaukos from $185.
00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company boosted their target price on shares of Glaukos from $153.
00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus increased their price target on shares of Glaukos from $153.
00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Piper Sandler dropped their price objective on shares of Glaukos from $180.
00 to $165.00 and set an “overweight” rating on the stock in a report on Tuesday, April 15th. Finally, Mizuho reduced their target price on shares of Glaukos from $200.
00 to $175.00 and set an “outperform” rating for the company in a research note on Wednesday, April 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock.
According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.17.
View Our Latest Analysis on GKOSAbout Glaukos (Free Report)Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.See AlsoFive stocks we like better than GlaukosHealth Care Stocks Explained: Why You Might Want to Invest2 Strong Utilities Plays With Booming Earnings and Room to GrowProcter & Gamble (NYSE:PG) Pulls Back After Shaky GuidanceWhy Smart Investors Don’t Panic in Election SeasonStock Splits, Do They Really Impact Investors?Now Is the Time to Buy ServiceNow—The Rebound Is Real.
